EGFR and fungal infectious disease: Inhibition of EGFR signaling with cetuximab or gefitinib, which are both FDA-approved inhibitors of EGFR, leads to a reduction in invasion and damage during fungal infection, and gefitinib prolonged survival in a mouse model [127].